All Episodes
|
52
|
John Marchica

Episode 52: Our Take, June 3, 2019

Jun 3, 2019

Episode Summary

In this week’s episode, John reviews Novartis’ new gene therapy for spinal muscular atrophy, priced at more than $2.1 million. ICER, a nonprofit research institute that evaluates the cost effectiveness of pharmaceuticals, said Novartis’ price is within the upper bound of the organization’s value-based price benchmark range.

Episode Notes

In this week’s episode, John reviews Novartis’ new gene therapy for spinal muscular atrophy, priced at more than $2.1 million. ICER, a nonprofit research institute that evaluates the cost effectiveness of pharmaceuticals, said Novartis’ price is within the upper bound of the organization’s value-based price benchmark range.

Briefs include:

  • A broad bipartisan draft health care legislation package containing dozens of provisions was recently released by the Senate Health Committee.
  • Forcing oncology practices to take on downside risk in CMS’ Oncology Care Model in July could result in more than half of them owing the government.
  • UnitedHealth Group pointed to price variations for diagnostic tests as a potential way to reduce overspending.
  • Mallinckrodt plans to spin off its specialty generics business to shareholders.
  • The FDA’s recent approval of Novartis’ Piqray (alpelisib).
  • FDA clears a new wearable device to treat migraine.
  • Biogen is scrapping its investigational treatment for Alzheimer’s disease, and is canceling its Phase III ENGAGE and EMERGE clinical trials.

About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

⚙️ Health Care Rounds is produced by Grippi Media

‍

Recommended Next

Why Nobody is Winning The Payer-Provider AI Arms Race w/ Dr. Marc Harrison, TowerBrook Healthcare Institute
Mailbag: Virtual Nurses, Bundled Payments, and Single Payer
When MisInformation Becomes a Health Crisis w/ Dr. Joshua Sharfstein, Johns Hopkins
Real Health Care Happens Between Doctor Visits w/ Wei-Li Shao, President, Omada Health
Mailbag: Debunking Vaccines Myths
Health Care's Affordability Crisis Is Getting Worse w/ Larry Levitt, CEO-Elect & EVP, KFF
Are We Measuring Health Care Quality All Wrong? w/ Dr. Rachel Werner, Professor of Medicine, UPenn
The State of Value-Based Health Care w/ John Marchica, Darwin Research Group

Recommended Content

Browse Library
INsights
September 28, 2026

Telix to merge with ITM in deal worth up to $2.35 billion

Read More
INsights
September 21, 2026

FDA approves first treatment targeting muscle loss in spinal muscular atrophy

Read More
INsights
September 14, 2026

OpenAI announces integration of ChatGPT for Healthcare with Epic’s EHR

Read More
Stay Aware. Stay Informed.

Subscribe to Our Take

Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.